Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial.
Mayank Saini, Jayanta Samanta, Antriksh Kumar...
https://pubmed.ncbi.nlm.nih.gov/37924855/Actively Recruiting
Led by The Cooper Health System · Updated on 2026-06-29
48
Participants Needed
1
Research Sites
4 weeks
Total Duration
This trial investigates the use of buprenorphine for pain relief in older adults aged 65 and above who have suffered acute fractures. The study aims to determine whether buprenorphine is as effective as hydromorphone, a full opioid agonist, in managing pain while possibly causing fewer side effects such as respiratory depression, sedation, delirium, and constipation. Older adults are often underrepresented in pain management studies despite their unique needs due to comorbidities and polypharmacy. Participants will receive either buprenorphine 0.15 mg IV or hydromorphone 0.25 mg IV every 15 minutes as needed for pain scores of 4 or greater, with a maximum of three doses. This randomized, single-blind study compares these two treatments over a 48-hour period to assess pain control and adverse side effects. The research is conducted in an emergency department setting where patients present with suspected or confirmed fractures. During the study, participants will be monitored for pain levels and side effects for up to 48 hours, with assessments including pain scores at 4 hours and evaluation of adverse events such as need for rescue medications or naloxone administration. Researchers will also track total opioid use and mortality up to 30 days. Participants may be asked about their pain and side effect experiences during this time to help determine the safety and effectiveness of buprenorphine compared to hydromorphone.
CONDITIONS
Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department
K
Katherine E Selman, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Cooper Health System
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Buprenorphine | Hydromorphone (Standard opioid control) |
|---|---|---|
| What is it? | A partial opioid agonist administered in low doses as an injection every 15 minutes as needed for moderate to severe pain after an acute fracture. | A full opioid agonist given as an intravenous injection every 15 minutes as needed for pain, serving as the standard opioid control in this trial. |
| Role in the trial | Investigational analgesic being compared to hydromorphone for acute fracture pain relief in older adults. | Active comparator arm, representing common emergency department opioid treatment for acute pain. |
| Primary use | To reduce moderate to severe pain from acute fractures in older adults. | To control moderate to severe pain from acute fractures as the standard opioid option. |
| How is it given or performed? | Injected as 0.15 mg every 15 minutes up to three doses, only if the pain score is 4 or higher. | Given as an intravenous injection of 0.25 mg every 15 minutes as needed for pain, up to a maximum of three doses. |
| Evidence status | While buprenorphine is being studied as an alternative for acute pain control, systematic reviews suggest it is effective for acute pain and may have fewer adverse effects compared to full opioid agonists, particularly in older adults. | Hydromorphone is a commonly used intravenous opioid with established effectiveness for treating moderate to severe acute pain in emergency department settings. |
| Important limitations | Adverse effect data for buprenorphine use in older adults with fractures are limited, and its use for acute fracture pain management is not yet established in this population. | Opioid analgesics like hydromorphone carry risks such as sedation, respiratory depression, and delirium, especially in older adults. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 48 hours
Participants receive either buprenorphine or hydromorphone intravenously as needed for pain scores of 4 or greater, up to three doses over 48 hours.
Assessments at regular intervals during treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Mayank Saini, Jayanta Samanta, Antriksh Kumar...
https://pubmed.ncbi.nlm.nih.gov/37924855/Mohammed S Albaqami, Adel A Alqarni, Musab S Alabeesy...
https://pubmed.ncbi.nlm.nih.gov/37032687/Marion A Coe, Michelle R Lofwall, Sharon L Walsh
https://pubmed.ncbi.nlm.nih.gov/30531584/L D White, A Hodge, R Vlok...
https://pubmed.ncbi.nlm.nih.gov/29576108/Katherine Selman, Sarah Perelman, Caroline Blatcher...
https://pubmed.ncbi.nlm.nih.gov/39024042/Rainer H Böger
https://pubmed.ncbi.nlm.nih.gov/16764217/A Dahan, A Yassen, R Romberg...
https://pubmed.ncbi.nlm.nih.gov/16547090/Mohammad Jalili, Marzieh Fathi, Maziar Moradi-Lakeh...
https://pubmed.ncbi.nlm.nih.gov/22115823/Martin Hale, Mark Garofoli, Robert B Raffa
https://pubmed.ncbi.nlm.nih.gov/34079354/The Cooper Health System
Lead Sponsor